Skip to main content
TipRanks
Go Ultimate75% OFF

Tempest Therapeutics (TPST) AI Stock Analysis

1,276 Followers
TPST

Tempest Therapeutics

(NASDAQ:TPST)

Select Model
Rating:41Neutral
Price Target:$0.33â–¼(-4.40% Downside)
Action:reiterated
Date:11/14/26

Overall score is driven primarily by weak financial performance (no revenue, continued losses and cash burn, and negative equity in TTM). Technicals add further pressure with a clear downtrend and negative momentum despite oversold readings. Corporate events provide some offset via pipeline and strategic progress, but are tempered by Nasdaq bid-price compliance risk; valuation remains unattractive/uninformative due to losses and no dividend.

Positive Factors
Expanded In Vivo CAR-T PlatformSecuring exclusive rights to a clinical-stage CD7 in vivo CAR-T platform broadens Tempest’s development portfolio and complements its existing delivery technology. If early observations are validated, the added candidates could create more clinical opportunities and strengthen the company’s position in an emerging therapeutic field.
Negative Factors
No Revenue and Persistent LossesTempest has not yet established a revenue base, while substantial operating losses continue as it funds research and clinical development. This limits operating leverage and means future progress depends on advancing programs toward commercialization before the business can sustainably cover its ongoing costs.

Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%TPST-90.73%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.83M
Dividend Yield
―
Average Volume (3M)
2.56M
Price to Earnings (P/E)
-0.1
Beta (1Y)
1.74
Revenue Growth
―
EPS Growth
61.31%
Country
US
Employees
4
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Tempest Therapeutics Business Overview & Revenue Model

Company Description

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a co...

Tempest Therapeutics Financial Statement Overview

Summary

Weak development-stage financial profile: no revenue in the periods provided, persistent large losses (TTM net loss -$40.6M) and ongoing cash burn (TTM operating/FCF about -$21.5M). Balance sheet risk is elevated with stockholders’ equity turning negative in TTM (-$1.8M) and a shrinking asset base, despite lower total debt versus prior years.

Income Statement

12Very Negative

Balance Sheet

18Very Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-22.24M0-389.00K000
EBITDA-39.55M-25.79M-40.14M-27.66M-33.45M-26.65M
Net Income-40.59M-26.26M-41.84M-29.49M-35.71M-28.30M
Balance Sheet
Total Assets8.76M16.93M41.49M51.60M46.09M73.24M
Cash, Cash Equivalents and Short-Term Investments897.00K7.71M30.27M39.23M31.23M51.83M
Total Debt7.26M8.14M15.37M20.66M22.11M18.54M
Total Liabilities10.59M10.26M22.36M24.84M27.98M37.12M
Stockholders Equity-1.83M6.67M19.13M26.77M18.11M36.12M
Cash Flow
Free Cash Flow-21.55M-26.82M-33.46M-27.53M-31.63M-26.09M
Operating Cash Flow-21.55M-26.82M-33.03M-27.36M-31.07M-25.96M
Investing Cash Flow00-435.00K-170.00K-562.00K-97.00K
Financing Cash Flow9.39M4.26M24.50M35.60M11.40M59.06M

Tempest Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.34

Price Trends

50DMA0.67Negative
100DMA0.84Negative
200DMA1.37Negative

Market Momentum

MACD-0.09Negative
RSI24.21Positive
STOCH18.39Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.67, and below the 200-day MA of 1.37, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 24.21 is Positive, neither overbought nor oversold. The STOCH value of 18.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.

Tempest Therapeutics Risk Analysis

Tempest Therapeutics disclosed 78 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.In the event that we fail to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing requirements of Nasdaq, our common stock may be delisted, which could affect our market price and liquidity.Q3, 2026
2.We experienced significant board and management turnover, and instability in governance and leadership could adversely affect our business.Q3, 2026
3.In the event that we fail to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing requirements of Nasdaq, our common stock may be delisted, which could affect our market price and liquidity.Q2, 2026

Tempest Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TPST against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ATNMATNM66Neutral$46.85M4.1983.42%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LTRNLTRN42Neutral$5.81M-0.26-456.35%――9.68%
PDSBPDSB42Neutral$97.04M-1.63-0.96%――32.24%
TPSTTPST41Neutral$6.83M-0.09-3552.74%――61.31%
CALCCALC39Underperform$8.21M-0.25-3029.57%――45.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%TPSTATNMPDSBLTRNCALCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TPST and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TPSTTempest Therapeutics, Inc.0.34-4.41-92.82%
ATNMActinium Pharmaceuticals1.490.139.56%
PDSBPds Biotechnology0.920.1723.20%
LTRNLantern Pharma, Inc.0.39-2.88-88.10%
CALCCalcimedica, Inc.1.19-14.59-92.46%

Tempest Therapeutics Corporate Events

Shareholder Meetings

Tempest Therapeutics Adjourns Special Meeting Over Voting Proposal

Neutral
Nov 16, 2026

On November 12, 2026, Tempest Therapeutics adjourned its reconvened special meeting after a quorum was established with 11,052,422 shares, or 74.64% of the 14,806,997 outstanding shares, present or represented by proxy, but there were insufficient vo...

Business Operations and StrategyProduct-Related Announcements

Tempest Therapeutics Exercises Rights to CD7 CAR-T Platform

Positive
Nov 12, 2026

On November 11, 2026, Tempest Therapeutics exercised its option under a September 14, 2026 Exclusive Collaboration, Option and License Agreement with Hebei Senlang Biotechnology Co., Ltd. to obtain exclusive rights outside China to develop and commer...

Executive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings

Tempest Therapeutics Stockholders Approve Key Corporate Proposals

Neutral
Nov 10, 2026

On November 9, 2026, stockholders of Tempest Therapeutics elected John David Yee and William Drake Richey as Class II directors. They also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year e...

Delistings and Listing ChangesRegulatory Filings and Compliance

Tempest Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

Negative
Nov 6, 2026

On November 4, 2026, Tempest Therapeutics received Nasdaq notice that its common stock had closed below $1 for 30 consecutive business days, breaching Nasdaq Listing Rule 5550(a)(2). The notice had no immediate effect on the stock’s Nasdaq listing or...

Executive/Board Changes

Tempest Therapeutics Announces CFO Resignation and Successor

Neutral
Oct 30, 2026

On October 26, 2026, Tempest Therapeutics announced that Chief Financial Officer Constance Ames resigned from all her positions at the company effective immediately, citing personal reasons unrelated to the business. On the same day, the board appoin...

Business Operations and StrategyShareholder Meetings

Tempest Therapeutics Faces Setback on Governance Reforms

Negative
Oct 20, 2026

On October 14, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally held on July 27, 2026, and previously adjourned on August 17 and September 15, to seek approval of an amendment removing certain supermajority voting re...

Business Operations and StrategyExecutive/Board Changes

Tempest Therapeutics Adds Veteran Executive to Board

Positive
Oct 19, 2026

On October 13, 2026, Tempest Therapeutics appointed veteran financial and operating executive John W. Frederick as a Class III director on its board, with his term running until the 2027 annual meeting of stockholders. As a non-employee director, Fre...

Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance

Tempest Therapeutics Strengthens Governance and CAR-T Partnership Framework

Positive
Sep 28, 2026

On Sept. 22, 2026, Tempest Therapeutics entered into a Master Services Agreement with related-party Factor Bioscience Inc. to provide research and development services, including Work Order No. 1 for in vivo CAR-T therapy development, with expected f...

Business Operations and StrategyProduct-Related Announcements

Tempest Therapeutics Expands In Vivo CAR-T Collaboration

Positive
Sep 17, 2026

On September 14, 2026, Tempest Therapeutics entered an exclusive collaboration, option and license agreement with Hebei Senlang Biotechnology that grants Tempest a four-month exclusive option to license Senlang’s CD7-targeted lentiviral in vivo CAR-T...

Business Operations and StrategyShareholder Meetings

Tempest Therapeutics Adjourns Meeting on Governance Changes

Negative
Sep 16, 2026

On September 15, 2026, Tempest Therapeutics reconvened a special shareholder meeting originally held on July 27 and August 17, 2026, to seek approval for an amendment to its Restated Certificate of Incorporation that would replace certain supermajori...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Tempest Therapeutics Announces New Private Warrant Financing

Positive
Sep 15, 2026

On September 11, 2026, Tempest Therapeutics entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and Series C and D common stock warrants, raising approximately $2.5 million in gro...

Business Operations and StrategyExecutive/Board Changes

Tempest Therapeutics Announces New Chief Financial Officer

Neutral
Aug 24, 2026

On August 18, 2026, Tempest Therapeutics, Inc. disclosed that Principal Financial Officer and Principal Accounting Officer Justin Trojanowski had resigned from all his roles at the company, with the departure scheduled to take effect on September 1,...

Business Operations and StrategyShareholder Meetings

Tempest Therapeutics Adjourns Special Stockholder Meeting Again

Negative
Aug 18, 2026

On August 17, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally convened and adjourned on July 27, 2026, to seek approval of an amendment to its Restated Certificate of Incorporation that would replace certain superma...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026